Back to results
US RE39,138 E1Granted
Monoclonal antibody specific for advanced glycosylation endproducts in biological samples
AssigneeAlteon Inc.
InventorsHenry W. Founds, Homayoun Sadeghi
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeAlteon Inc.
InventorsHenry W. Founds, Homayoun Sadeghi
Estimating the term…
The present invention relates to monoclonal antibodies to advanced glycosylation endproducts formed in vivo and cross-reactive with advanced glycosylation endproducts formed in vitro, and to methods of diagnosis and therapy based thereon. More particularly, the invention is directed to a monoclonal antibody, or an antigen-binding fragment thereof, reactive with in vivo produced advanced glycosylation endproducts (AGEs), which monoclonal antibody or antigen binding fragment thereof demonstrates an immunological binding characteristic of monoclonal antibody 4G9 as produced by hybridoma 4G9, deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626, on Apr. 27, 1994. In a specific embodiment, the 4G9 antibody is used in a sandwich ELISA to detect ApoB-AGE, IgG-AGE, collagen-AGE, serum-AGE peptides and proteins and urinary-AGE peptides and proteins.
Monoclonal antibody 4G9 produced by hybridoma 4G9, deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626, or an antigen binding fragment thereof reactive with in vivo produced advanced glycosylation endproducts (AGEs).
A hybridoma deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626.
A monoclonal antibody, or an antigen binding fragment thereof reactive with in vivo produced advanced glycosylation endproducts (AGEs), wherein the antibody or fragment is selected such that antigen binding measured by binding competition by 6-aminocaproic acid browned with glucose matches that of
Dependencies are inferred from the claim text.